Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
$5.81
-5.1%
$7.46
$5.63
▼
$9.32
$493.55M1.04604,637 shs361,640 shs
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
$12.85
-5.5%
$22.07
$12.82
▼
$28.23
$1.61B1.83.86 million shs2.43 million shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$13.33
-5.9%
$17.90
$13.25
▼
$24.68
$1.62B0.451.86 million shs2.24 million shs
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$8.37
-5.6%
$10.96
$5.45
▼
$14.38
$1.64B1.72.94 million shs3.09 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
-5.07%-28.71%-24.84%-13.67%-6.29%
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-5.51%-16.99%-50.61%-51.91%-10.33%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-5.93%-17.05%-28.18%-29.06%-18.67%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-5.61%-15.94%-20.79%-14.40%+53.90%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
$5.81
-5.1%
$7.46
$5.63
▼
$9.32
$493.55M1.04604,637 shs361,640 shs
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
$12.85
-5.5%
$22.07
$12.82
▼
$28.23
$1.61B1.83.86 million shs2.43 million shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$13.33
-5.9%
$17.90
$13.25
▼
$24.68
$1.62B0.451.86 million shs2.24 million shs
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$8.37
-5.6%
$10.96
$5.45
▼
$14.38
$1.64B1.72.94 million shs3.09 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
-5.07%-28.71%-24.84%-13.67%-6.29%
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-5.51%-16.99%-50.61%-51.91%-10.33%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-5.93%-17.05%-28.18%-29.06%-18.67%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-5.61%-15.94%-20.79%-14.40%+53.90%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
2.80
Moderate Buy$18.00209.81% Upside
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
2.87
Moderate Buy$34.43167.93% Upside
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.00
Hold$23.8078.54% Upside
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.78
Moderate Buy$22.57169.61% Upside

Current Analyst Ratings Breakdown

Latest EPRX, VIR, SRPT, and NRIX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/19/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Boost Price TargetNeutral$20.00 ➝ $22.00
11/16/2026
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
Reiterated RatingOutperform
11/12/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
UpgradeSell (E+) ➝ Sell (D)
11/11/2026
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
Boost Price TargetBuy$11.00 ➝ $16.00
11/10/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
UpgradeSell ➝ Hold$14.00 ➝ $18.00
11/10/2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Boost Price TargetOverweight$25.00 ➝ $28.00
11/9/2026
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
Initiated CoverageOutperform$14.00
11/9/2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Reiterated RatingBuy$22.00
11/6/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Set Price Target$18.00
11/6/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Boost Price TargetSector Perform$17.00 ➝ $18.00
11/5/2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Boost Price TargetBuy$18.00 ➝ $20.00
(Data available from 11/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
N/AN/AN/AN/A$1.36 per shareN/A
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
$83.98M16.72N/AN/A$5.29 per share2.43
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$2.20B0.65N/AN/A$14.26 per share0.93
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$68.56M20.91N/AN/A$5.23 per share1.60
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
-$38.58M-$1.06N/AN/AN/AN/A-67.78%-46.73%N/A
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-$264.46M$2.315.56N/AN/A42.01%49.34%38.61%1/27/2027 (Estimated)
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-$713.41M-$1.37N/A12.340.37-5.86%-0.20%-0.09%N/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$437.99M-$1.26N/AN/AN/AN/A-21.38%-16.97%N/A

Latest EPRX, VIR, SRPT, and NRIX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
-$0.26-$0.23+$0.03-$0.23N/AN/A
11/5/2026Q3 2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$0.0790$0.13+$0.0510-$0.27$352.20 million$381.35 million
11/4/2026Q3 2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$0.7493-$0.57+$0.1793-$0.57$0.98 million($0.19) million
10/13/2026Q3 2026
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-$0.6009$4.73+$5.3309$4.73$24.35 million$673.06 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
N/AN/AN/AN/AN/A
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/AN/AN/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
0.03
12.25
12.25
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/A
8.44
8.44
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.46
3.46
2.13
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/A
6.30
6.30

Institutional Ownership

CompanyInstitutional Ownership
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
N/A
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
65.32%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
4967.24 millionN/AN/A
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
357109.25 million101.93 millionOptionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
835107.24 million99.84 millionOptionable
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
367171.27 million166.30 millionOptionable

Recent News About These Companies

Vir Biotechnology stock: USD 150 million offering priced
Why is Vir Biotechnology stock falling Friday?
Vir Biotechnology stock tumbles on $150M share offering
HC Wainwright Has Optimistic Opinion of VIR FY2026 Earnings
Vir Biotechnology Announces Proposed Public Offering
TD Cowen Reaffirms Their Buy Rating on Vir Biotechnology (VIR)
Is Vir Biotechnology (VIR) Overvalued After Its 127% Run?
What is HC Wainwright's Estimate for VIR FY2026 Earnings?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Eupraxia Pharmaceuticals stock logo

Eupraxia Pharmaceuticals NASDAQ:EPRX

$5.81 -0.31 (-5.07%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$5.71 -0.10 (-1.77%)
As of 11/20/2026 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Nurix Therapeutics stock logo

Nurix Therapeutics NASDAQ:NRIX

$12.85 -0.75 (-5.51%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$12.88 +0.03 (+0.24%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Sarepta Therapeutics stock logo

Sarepta Therapeutics NASDAQ:SRPT

$13.33 -0.84 (-5.93%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$13.59 +0.26 (+1.95%)
As of 11/20/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Vir Biotechnology stock logo

Vir Biotechnology NASDAQ:VIR

$8.37 -0.50 (-5.61%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$8.48 +0.10 (+1.23%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.